$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter

Equities research analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will announce $876.57 million in sales for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $847.72 million to $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current financial year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts expect that the business will report sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The business had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 EPS.

Several research firms have recently commented on ALXN. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective for the company in a research note on Monday, December 18th. Leerink Swann restated a “buy” rating and issued a $169.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. BMO Capital Markets restated an “outperform” rating and issued a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, SunTrust Banks restated a “buy” rating and issued a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $155.70.

A number of hedge funds have recently modified their holdings of the business. Rathbone Brothers plc increased its stake in Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 50 shares in the last quarter. Evercore Wealth Management LLC increased its stake in Alexion Pharmaceuticals by 8.1% in the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 125 shares in the last quarter. Wealthsource Partners LLC increased its stake in Alexion Pharmaceuticals by 4.4% in the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 126 shares in the last quarter. National Asset Management Inc. increased its stake in Alexion Pharmaceuticals by 5.1% in the 2nd quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 162 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its stake in Alexion Pharmaceuticals by 2.4% in the 2nd quarter. Tudor Investment Corp ET AL now owns 7,207 shares of the biopharmaceutical company’s stock worth $877,000 after buying an additional 170 shares in the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down $0.67 on Friday, reaching $119.59. 1,082,217 shares of the company’s stock were exchanged, compared to its average volume of 1,989,982. The stock has a market cap of $26,867.24, a price-to-earnings ratio of 53.39, a PEG ratio of 1.31 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34.

COPYRIGHT VIOLATION NOTICE: “$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/14/876-57-million-in-sales-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter-updated-updated.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply